Risks Associated with Triglyceride Concentration

Triglyceride Concentration¹

Associated Risks

Severe Hypertriglyceridemia

500 – 1000mg / 1dL blood

5.56 – 11.3mmol / 1L blood

Increased risk of:

- Cardiovascular disease
- Pancreatitis
- Metabolic Associated
 Steatohepatitis (MASH)^{2,3}

High Levels

200 – 499mg / 1dL blood

2.2 – 5.6mmol / 1L blood Heightened risk for cardiovascular disease³ (heart attack / MI, stroke, angina)¹

Borderline Levels

150 – 199mg / 1dL blood

1.7 – 2.2mmol / 11. blood

- Some risk of cardiovascular disease⁴ and may show some signs of metabolic syndrome:
 - Low levels of HDL cholesterol
 - Heightened levels of fasting glucose levels
 - High blood pressure
 - Elevated waist circumference⁵

Optimal Levels¹

<100mg/

<1.2mmol/ 1L blood



INTERNATIONAL

eferences

¹Aggarwal, R., et al – Triglycerides Revisited: A contemporary perspective on the assessment and management of cardiovascular risk due to elevated triglycerides: A consensus state of the International Atherosclerosis Society. IAS; 2024 [cited 2025 June 6th]. Available from https://athero.org/wp-content/uploads/2024/07/IAS_Triglycerides-Revisited-Consensus_Aug2024.pdf

² Gurevitz, C. and Rosenson, R.S.: Metabolic dysfunction-associated steatotic liver disease, hypertriglyceridaemia, and

² Gurevitz, C. and Rosenson, R.S.: Metabolic dysfunction-associated steatotic liver disease, hypertriglyceridaemia, and cardiovascular risk. European Journal of Preventative Cardiology, 2024 [cited 2025 June 6th]. Available from https://academic.oup.com/eurjpc/advance-article-abstract/doi/10.1093/eurjpc/zwae388/7916524

³ Hernandez, P., et al – Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Current Atherosclerosis

Reports. Springer; 2021 [cited 2025 June 6th]. Available from: https://link.springer.com/article/10.1007/s11883-021-00962-z

* Nelson AJ, Navar AM, Mulder H, et al. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2
Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2
Diabetes [BARI 2D] Trial). Am J Cardiol. 2020;132:36-43. doi: 10.1016/j.amjcard.2020.07.005.

* Lam, DW, and LeRoith, D – Metabolic Syndrome. In: Endotext, MDText.com, inc., South Dartmouth (MA); 2000 [cited 2025 June 6th]. Available from: https://europepmc.org/article/NBK/nbk278936

